[go: up one dir, main page]

RU2012121055A - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION Download PDF

Info

Publication number
RU2012121055A
RU2012121055A RU2012121055/15A RU2012121055A RU2012121055A RU 2012121055 A RU2012121055 A RU 2012121055A RU 2012121055/15 A RU2012121055/15 A RU 2012121055/15A RU 2012121055 A RU2012121055 A RU 2012121055A RU 2012121055 A RU2012121055 A RU 2012121055A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
methylpyridine
ethyl
succinate
composition according
Prior art date
Application number
RU2012121055/15A
Other languages
Russian (ru)
Other versions
RU2504375C1 (en
Inventor
Галина Викторовна Сукоян
Людмила Дмитриевна Лукьянова
Виктор Викторович Арсеенков
Original Assignee
Галина Викторовна Сукоян
Людмила Дмитриевна Лукьянова
Виктор Викторович Арсеенков
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галина Викторовна Сукоян, Людмила Дмитриевна Лукьянова, Виктор Викторович Арсеенков filed Critical Галина Викторовна Сукоян
Priority to RU2012121055/15A priority Critical patent/RU2504375C1/en
Publication of RU2012121055A publication Critical patent/RU2012121055A/en
Application granted granted Critical
Publication of RU2504375C1 publication Critical patent/RU2504375C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Фармацевтический состав для лечения заболеваний, связанных с эндотелиальной дисфункцией, характеризующийся тем, что в качестве активного ингредиента содержит производное метилпиридина или его фармацевтически приемлемую соль, пурин и вспомогательные вещества, находится в виде стабильной лекарственной формы при следующем соотношении компонентов, мас.%:2. Фармацевтический состав по п.1, характеризующийся тем, что в качестве активного вещества, содержит соединения из группы: 3-(N,N-диметилкарбомоилокси)-2-этил-6-метилпиридина сукцинат, 3-метилпиридин сукцинат, 2-этил-6-метил-3-гидроксипиридина гидрохлорид, 6-трихлорметил-2-хлорпиридин (нитрапирин), 2-этил-6-метил-3-гидроксипиридина сукцинат.3. Фармацевтический состав по п.1, характеризующийся тем, что в качестве пурина содержит инозин, аденозин, гипоксантин, преимущественно инозин.4. Фармацевтический состав по п.1, характеризующийся тем, что находится в виде инъекций, лиофилизата, твердых капсул, таблеток, суппозиторий.1. The pharmaceutical composition for the treatment of diseases associated with endothelial dysfunction, characterized in that the active ingredient contains a methylpyridine derivative or its pharmaceutically acceptable salt, purine and excipients, is in the form of a stable dosage form in the following ratio, wt.%: 2. The pharmaceutical composition according to claim 1, characterized in that, as an active substance, contains compounds from the group: 3- (N, N-dimethylcarbomoyloxy) -2-ethyl-6-methylpyridine succinate, 3-methylpyridine succinate, 2-ethyl-6 -methyl-3-hydroxypyridine hydrochloride, 6-trichloromethyl-2-chloropyridine (nitrapyrin), 2-ethyl-6-methyl-3-hydroxypyridine succinate. 3. The pharmaceutical composition according to claim 1, characterized in that as purine contains inosine, adenosine, hypoxanthine, mainly inosine. The pharmaceutical composition according to claim 1, characterized in that it is in the form of injections, lyophilisate, hard capsules, tablets, suppository.

Claims (4)

1. Фармацевтический состав для лечения заболеваний, связанных с эндотелиальной дисфункцией, характеризующийся тем, что в качестве активного ингредиента содержит производное метилпиридина или его фармацевтически приемлемую соль, пурин и вспомогательные вещества, находится в виде стабильной лекарственной формы при следующем соотношении компонентов, мас.%:1. The pharmaceutical composition for the treatment of diseases associated with endothelial dysfunction, characterized in that the active ingredient contains a methylpyridine derivative or its pharmaceutically acceptable salt, purine and excipients, is in the form of a stable dosage form in the following ratio, wt.%: Производное метилпиридинаMethylpyridine derivative или его фармацевтически приемлемая сольor its pharmaceutically acceptable salt 1,0-6,01.0-6.0 пуринpurin 10,0-80,010.0-80.0 Вспомогательные веществаExcipients остальноеrest
2. Фармацевтический состав по п.1, характеризующийся тем, что в качестве активного вещества, содержит соединения из группы: 3-(N,N-диметилкарбомоилокси)-2-этил-6-метилпиридина сукцинат, 3-метилпиридин сукцинат, 2-этил-6-метил-3-гидроксипиридина гидрохлорид, 6-трихлорметил-2-хлорпиридин (нитрапирин), 2-этил-6-метил-3-гидроксипиридина сукцинат.2. The pharmaceutical composition according to claim 1, characterized in that, as an active substance, contains compounds from the group: 3- (N, N-dimethylcarbomoyloxy) -2-ethyl-6-methylpyridine succinate, 3-methylpyridine succinate, 2-ethyl -6-methyl-3-hydroxypyridine hydrochloride, 6-trichloromethyl-2-chloropyridine (nitrapyrin), 2-ethyl-6-methyl-3-hydroxypyridine succinate. 3. Фармацевтический состав по п.1, характеризующийся тем, что в качестве пурина содержит инозин, аденозин, гипоксантин, преимущественно инозин.3. The pharmaceutical composition according to claim 1, characterized in that as purine contains inosine, adenosine, hypoxanthine, mainly inosine. 4. Фармацевтический состав по п.1, характеризующийся тем, что находится в виде инъекций, лиофилизата, твердых капсул, таблеток, суппозиторий. 4. The pharmaceutical composition according to claim 1, characterized in that it is in the form of injections, lyophilisate, hard capsules, tablets, suppository.
RU2012121055/15A 2012-05-23 2012-05-23 Pharmaceutical formulation for treating diseases associated with endothelial dysfunction RU2504375C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2012121055/15A RU2504375C1 (en) 2012-05-23 2012-05-23 Pharmaceutical formulation for treating diseases associated with endothelial dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012121055/15A RU2504375C1 (en) 2012-05-23 2012-05-23 Pharmaceutical formulation for treating diseases associated with endothelial dysfunction

Publications (2)

Publication Number Publication Date
RU2012121055A true RU2012121055A (en) 2013-11-27
RU2504375C1 RU2504375C1 (en) 2014-01-20

Family

ID=49624994

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012121055/15A RU2504375C1 (en) 2012-05-23 2012-05-23 Pharmaceutical formulation for treating diseases associated with endothelial dysfunction

Country Status (1)

Country Link
RU (1) RU2504375C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657416C1 (en) * 2017-02-20 2018-06-13 Общество с ограниченной ответственностью "АЛВИЛС" Method of treatment of endothelial dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2905936B1 (en) * 1979-02-16 1980-04-30 Degussa Process for lightening and deodorising sulfate pulp
RU2095350C1 (en) * 1993-10-13 1997-11-10 Центр по химии лекарственных средств (ЦХЛС-ВНИХФИ) 3-(n,n-dimethylcarbamoylhydroxy)-2-ethyl-6-methylpyridine succinate showing antihypoxic activity
RU2280455C2 (en) * 2004-02-05 2006-07-27 Галина Викторовна Сукоян Medicinal agent for arresting syndrome of systemic inflammatory response

Also Published As

Publication number Publication date
RU2504375C1 (en) 2014-01-20

Similar Documents

Publication Publication Date Title
SA519402405B1 (en) HIV inhibitor compounds
WO2017112917A8 (en) Methods of treating cancer
MX2015005949A (en) Antiviral azasugar-containing nucleosides.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
UA99141C2 (en) SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
EA201500304A1 (en) ANALOGUES OF 2'-CHLORINE NUCLEOSIDE FOR HCV INFECTION
MA37405A1 (en) Heterocyclyl compounds
RU2018120153A (en) METHODS FOR TREATING A MALIGNANT TUMOR USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITING ACTIVITY
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
RU2012121055A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION
MX391191B (en) EXTENDED-RELEASE COMPOSITIONS OF ONAPRISTONE AND METHODS.
MY191983A (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
RU2010129409A (en) METHOD FOR TREATING RABBIT PSOROPTOSIS AND CARNIVOR ANIMAL OTODEKTOSIS
RU2013124416A (en) DIINDOLYLMETHANE MEDICINAL PRODUCT AND ITS APPLICATION FOR TREATMENT OF INFLUENZA AND RESPIRATORY VIRAL INFECTIONS
RU2012145513A (en) METHOD FOR PRODUCING INTEGRATED PRODUCT WITH IMMUNOMETABOLIC AND ANTHELMINTIC ACTIVITY
RU2012136190A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ARTHROZOARTHRITIS CONTAINING REBAMIPID AS AN ACTIVE INGREDIENT
RU2015157534A (en) DRUG FOR TREATMENT OF BONE NOSES, HEADACHES AND PAINS IN THE HEART
RU2012118228A (en) HIGHLY STABLE PHARMACEUTICAL COMPOSITION BASED ON THE LYOPHYLISATE OF 3-OXYPRIDINES OR METHYLPYRIDINES OR THEIR PHARMACEUTALLY ACCEPTABLE SALTS
RU2010131342A (en) PHARMACEUTICAL COMPOSITION (OPTIONS) FOR PREVENTION AND TREATMENT OF DISEASES OF THE NERVOUS SYSTEM AND METHOD OF ITS PRODUCTION
RU2011128758A (en) PHARMACEUTICAL ANTI-TUBERCULOSIS COMBINED COMPOSITION
RU2013157796A (en) PHARMACEUTICAL COMPOSITION BASED ON MOXIFLOXACIN
RU2013121820A (en) COMBINED MEDICINE FOR THE ELIMINATION OF SYMPTOMS AND TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS AND INFLUENZA
RU2016146653A (en) PHARMACEUTICAL COMPOSITION BASED ON CHLORBENZOYLAMINOADAMANTHANE, INCREASING PHYSICAL PERFORMANCE IN THE CONDITIONS OF HIGH AND LOW TEMPERATURES
AR132685A2 (en) PHARMACEUTICAL FORMULATIONS OF A BRUTON TYROSINE KINASE INHIBITOR

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190524